A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors

Vered Stearns, C. Isaacs, J. Rowland, J. Crawford, M. J. Ellis, R. Kramer, W. Lawrence, J. J. Hanfelt, D. F. Hayes

Research output: Contribution to journalArticle

Abstract

Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes. Patients and methods: Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine's efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study. Results: Twenty-seven women completed the six-week study period. The mean reduction of hot flash frequency was 67% (95% confidence interval (95% CI): 56%-79%). The mean reduction in hot flash severity score was 75% (95% CI: 66%85%). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83%) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse effect was somnolence, resulting in drug discontinuation in two women, and dose reduction in two women. One woman discontinued drug due to anxiety. Conclusions: Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalAnnals of Oncology
Volume11
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Hot Flashes
Paroxetine
Survivors
Breast Neoplasms
Anxiety
Quality of Life
Pharmaceutical Preparations
Confidence Intervals
Symptom Assessment
Serotonin Uptake Inhibitors
Therapeutics
Sleep
Estrogens
Randomized Controlled Trials
Placebos
Depression

Keywords

  • Breast cancer
  • Hot flashes
  • Paroxetine
  • Serotonin uptake inhibitors
  • Survivors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. / Stearns, Vered; Isaacs, C.; Rowland, J.; Crawford, J.; Ellis, M. J.; Kramer, R.; Lawrence, W.; Hanfelt, J. J.; Hayes, D. F.

In: Annals of Oncology, Vol. 11, No. 1, 2000, p. 17-22.

Research output: Contribution to journalArticle

Stearns, V, Isaacs, C, Rowland, J, Crawford, J, Ellis, MJ, Kramer, R, Lawrence, W, Hanfelt, JJ & Hayes, DF 2000, 'A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors', Annals of Oncology, vol. 11, no. 1, pp. 17-22. https://doi.org/10.1023/A:1008382706068
Stearns, Vered ; Isaacs, C. ; Rowland, J. ; Crawford, J. ; Ellis, M. J. ; Kramer, R. ; Lawrence, W. ; Hanfelt, J. J. ; Hayes, D. F. / A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. In: Annals of Oncology. 2000 ; Vol. 11, No. 1. pp. 17-22.
@article{027e39968d6e477794f31b1daaac8f68,
title = "A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil{\circledR}) in controlling hot flashes in breast cancer survivors",
abstract = "Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes. Patients and methods: Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine's efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study. Results: Twenty-seven women completed the six-week study period. The mean reduction of hot flash frequency was 67{\%} (95{\%} confidence interval (95{\%} CI): 56{\%}-79{\%}). The mean reduction in hot flash severity score was 75{\%} (95{\%} CI: 66{\%}85{\%}). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83{\%}) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse effect was somnolence, resulting in drug discontinuation in two women, and dose reduction in two women. One woman discontinued drug due to anxiety. Conclusions: Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.",
keywords = "Breast cancer, Hot flashes, Paroxetine, Serotonin uptake inhibitors, Survivors",
author = "Vered Stearns and C. Isaacs and J. Rowland and J. Crawford and Ellis, {M. J.} and R. Kramer and W. Lawrence and Hanfelt, {J. J.} and Hayes, {D. F.}",
year = "2000",
doi = "10.1023/A:1008382706068",
language = "English (US)",
volume = "11",
pages = "17--22",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors

AU - Stearns, Vered

AU - Isaacs, C.

AU - Rowland, J.

AU - Crawford, J.

AU - Ellis, M. J.

AU - Kramer, R.

AU - Lawrence, W.

AU - Hanfelt, J. J.

AU - Hayes, D. F.

PY - 2000

Y1 - 2000

N2 - Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes. Patients and methods: Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine's efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study. Results: Twenty-seven women completed the six-week study period. The mean reduction of hot flash frequency was 67% (95% confidence interval (95% CI): 56%-79%). The mean reduction in hot flash severity score was 75% (95% CI: 66%85%). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83%) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse effect was somnolence, resulting in drug discontinuation in two women, and dose reduction in two women. One woman discontinued drug due to anxiety. Conclusions: Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.

AB - Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes. Patients and methods: Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine's efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study. Results: Twenty-seven women completed the six-week study period. The mean reduction of hot flash frequency was 67% (95% confidence interval (95% CI): 56%-79%). The mean reduction in hot flash severity score was 75% (95% CI: 66%85%). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83%) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse effect was somnolence, resulting in drug discontinuation in two women, and dose reduction in two women. One woman discontinued drug due to anxiety. Conclusions: Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.

KW - Breast cancer

KW - Hot flashes

KW - Paroxetine

KW - Serotonin uptake inhibitors

KW - Survivors

UR - http://www.scopus.com/inward/record.url?scp=0033981088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033981088&partnerID=8YFLogxK

U2 - 10.1023/A:1008382706068

DO - 10.1023/A:1008382706068

M3 - Article

C2 - 10690382

AN - SCOPUS:0033981088

VL - 11

SP - 17

EP - 22

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -